Table 4. Dose of cisplatin estimated to cause nephrotoxicity in 32 risk groups.

Group	Pre_scra(mg/dL)	BMIb (kg/m2)	MgOc	NSAIDsd	Cisplatin dose estimated to cause nephrotoxicity (mg/m2)
1	0.56 first quartile (0–25%)	22.27 above the median	with	with	50.33#
2				without	68.70
3			without	with	26.58#
4				without	44.95#
5		17.47 below the median	with	with	67.73
6				without	86.10
7			without	with	43.98#
8				without	62.35
9	0.63 second quartile (25–50%)	22.27 above the median	with	with	57.77#
10				without	76.14
11			without	with	34.02#
12				without	52.39#
13		17.47 below the median	with	with	75.17
14				without	93.54
15			without	with	51.42#
16				without	69.79
17	0.78 third quartile (50–75%)	22.27 above the median	with	with	73.68
18				without	92.06
19			without	with	49.93#
20				without	68.31
21		17.47 below the median	with	with	91.08
22				without	109.46
23			without	with	67.33
24				without	85.71
25	0.89 fourth quartile (75–100%)	22.27 above the median	with	with	84.83
26				without	103.21
27			without	with	61.08
28				without	79.46
29		17.47 below the median	with	with	102.23
30				without	120.61
31			without	with	78.48
32				without	96.86

^abaseline serum creatinine,

^bbody mass index,

^cmagnesium oxide,

^dnonsteroidal anti-inflammatory drugs.